ImmunityBio's NMIBC Trial Hits Key Statistical Milestone: ANKTIVA Plus BCG Study Moves Forward Without More Enrollment
Study Achieves Required Statistical Power for Regulatory Submission
ImmunityBio (NASDAQ: IBRX) announced that its pivotal QUILT-2.005 trial investigating ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guerin (BCG) for BCG-naive non-muscle invasive bladder cancer (NMIBC) has met a significant milestone. The company confirmed no additional patients will be enrolled, as the Independent Data Monitoring Committee (IDMC) determined the study’s current size of 366 participants provides adequate statistical power to detect meaningful differences in treatment outcome.
IDMC Interim Analysis Backs Power and Efficacy Endpoints
The QUILT-2.005 trial, a randomized, controlled Phase 2b study, is designed to assess whether adding ANKTIVA to standard BCG induction improves complete response (CR) rates in BCG-naive NMIBC patients with carcinoma in situ (CIS), with or without papillary disease. In March 2026, an interim analysis reviewed data from 183 evaluable patients (the pre-specified 50% threshold) within Cohort A. The IDMC concluded there is sufficient enrollment to meet the study’s efficacy endpoints, eliminating the need for additional participants and ensuring a clean path toward regulatory review.
Enrollment Complete; Final Results & BLA Filing Expected Q4 2026
With enrollment complete as of February 2026, ImmunityBio expects to conduct final analysis and submit a supplemental Biologics License Application (BLA) in Q4 2026. The completion of enrollment marks a critical step in the company’s plan to potentially expand ANKTIVA's label from BCG-unresponsive to BCG-naive settings — a substantially larger patient group. This progress follows encouraging long-term response and survival data, including a 100% complete remission rate (median survival 8.8 years) among participants from the initial Phase 1b cohort enrolled in 2014 who entered long-term follow-up.
Key Trial Data and Milestones
| Milestone | Details |
|---|---|
| Trial Name | QUILT-2.005 (NCT02138734) |
| Total Enrollment | 366 patients |
| Interim Analysis Cutoff | 50% of enrolled (183 patients) as of March 2026 |
| Power Confirmation | Sufficient to detect clinically meaningful differences in CR rate |
| Planned BLA Submission | Q4 2026 |
| Population Focus | BCG-naive NMIBC, CIS with/without papillary disease |
Expanding Therapeutic Reach: What’s at Stake?
ANKTIVA is already approved in the BCG-unresponsive NMIBC setting across 34 countries. If the trial’s final data confirm a meaningful boost in complete response rates when combined with BCG in BCG-naive patients, ImmunityBio could address a much broader group of patients earlier in their treatment journey. For investors and industry watchers, this development represents a critical inflection point for the company’s commercial prospects.
Biological Mechanism Underpins Durable Responses
ANKTIVA acts as an IL-15 receptor agonist, activating natural killer (NK) cells and CD8+ T cells, which in turn strengthen the immune system’s ability to eliminate bladder cancer cells and establish long-term immune memory. This mechanism, validated over a decade of development, now shows consistency in producing durable remissions — including 100% long-term complete responses in early trial cohorts — supporting the optimism for the upcoming BLA submission.
Takeaway: Key Regulatory Milestone Sets Stage for Broader Approval
The confirmation of adequate statistical power and the completion of enrollment mean ImmunityBio’s ANKTIVA-BCG program finds itself on a straightforward regulatory track. Final data could lay the groundwork for regulatory approval in the BCG-naive NMIBC setting, setting up the company for a potentially transformative expansion. Investors, clinicians, and patients alike will be watching closely as the company prepares its pivotal data for submission in the months ahead.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI